Growing evidence suggests late-life mood disorders (LLMDs), such as depression and bipolar disorder, could be early warning signs of neurodegenerative diseases like dementia – even when they appear… read more.
SpringWorks Therapeutic Inc. announced the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) Annual Congress in… read more.
A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington’s disease and improve the efficiency of clinical trials,… read more.
NICE (UK): Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and… read more.
When it comes to advanced cancer or Alzheimer’s disease, over half of doctors would consider assisted dying for themselves, but preferences seem to vary according to their jurisdiction’s… read more.
NICE(UK): Cenobamate is recommended as an option as an add-on treatment for focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has… read more.
Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their… read more.
Antidepressants that suppress REM (rapid eye movement) sleep appear to improve survival in people with amyotrophic lateral sclerosis (ALS). Researchers reported the finding on May 21, 2025 at… read more.
The total economic burden of Alzheimer’s disease and related dementias in the United States will reach $781 billion this year, according to new USC-led research. This is the… read more.
Roche announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
